Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
by on Wednesday, May 30th, 2012 | No Comments
Condition: Chronic Myeloid Leukemia (CML)
Intervention: Drug: AMN107
Sponsors: Novartis; Novartis Pharmaceuticals; Name/Official Title: Socorro Portella – Oncology Medical Director; Organization: Novartis Biociências SA - Brazil; Contact Information: 5511-55324205
Not yet recruiting – verified May 2012
See the original post: Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.